Professor Maria Domenica Cappellini joined touchONCOLOGY at ASH 2018 to discuss haematologists’ approach to Gaucher disease, focusing on the diagnosis and follow-up of this rare genetic condition. Professor Cappellini outlines the current issue of slow diagnosis times, and emphasises the importance of faster diagnosis in order to start treatment earlier and prevent disease-related complications, improving quality of life. She warns that, although rare, the rarity of the disease is not as expected as it is often under diagnosed, and that physician awareness, especially in haematologists, is the most important next step for the disease. Briefly, she discusses how it can be distinguished from other similar conditions and the most useful current diagnostic tests for Gaucher disease.
1. What is the average time to diagnosis in patients presenting with Gaucher disease type 1 and what is the impact of this on treatment? (0:10)
2. Why is diagnosis often delayed in patients with Gaucher disease? (1:55)
3. What symptoms should prompt the physician to suspect Gaucher disease? (0:10)
4. How can Gaucher disease be distinguished from clinically similar conditions such as other lysosomal storage disorders and haematological malignancies? (1:31)
5. What are the most useful diagnostic tests for Gaucher disease? (3:37)
Speaker’s disclosures: Maria Domenica Cappellini has received honoraria for advisory boards from Novartis Pharmaceuticals, Sanofi Genzyme and Celgene.
Support: This video interview was supported by Sanofi Genzyme.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018
Share this Video
Related Videos In Haematology
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!